Table 1

Effect of SGLT2i in NAFLD

Author, yearAgentnDuration (weeks)ComparatorMain study results
Body weight*ALTLiver fat*
Prospective open-label studies
Ito et al., 2017 (42)Ipragliflozin6624Pioglitazone↓ 3.7%
Ohta et al., 2017 (43)Ipragliflozin2024Standard care↓ 2.5%↓ 39%
Shibuya et al., 2018 (44)Luseogliflozin3224Standard care↓ 3.2%Unchanged
Kuchay et al., 2018 (45)Empagliflozin5020Standard care↓ 1.1%↓ 26%
Shimizu et al., 2019 (46)Dapagliflozin5724Standard care↓ 3.1%
Inoue et al., 2019 (47)Canagliflozin2052Standard care↓ 3.4%↓ 31%
Randomized controlled trials
Bolinder et al., 2012 (48)Dapagliflozin6724Placebo↓ 2.2%Unchanged
Eriksson et al., 2018 (49)Dapagliflozin8412Placebo↓ 2.2%↓ 10%§
Cusi et al., 2019 (50)Canagliflozin5624Placebo↓ 3.4%Unchanged↓ 18%§
Latva-Rasku et al., 2019 (51)Dapagliflozin328Placebo↓ 2.1%Unchanged↓ 13%
Kahl et al., 2019 (52)Empagliflozin8424Placebo↓ 2.4%Unchanged↓ 22%
  • Arrows indicate statistically significant changes vs. comparator.

  • * Comparison-corrected (open-label) or placebo-corrected relative treatment difference in weight and liver fat measured with MRI-based imaging techniques.

  • Liver fat measured as liver-to-spleen attenuation ratio on computed tomography. In Ito et al. (42) the decrease in liver fat was similar to pioglitazone (comparator).

  • Significant improvement in liver fat by controlled attenuation parameter (CAP; Fibroscan).

  • § Not significant compared with placebo.